

**Listing of the Claims:**

What is claimed is:

1. **(PREVIOUSLY PRESENTED)** A non-invasive method for facilitating the diagnosis of a subject for a tissue remodeling-associated condition, comprising:
  - obtaining a urine sample from a subject;
  - contacting the urine sample with an antibody specifically reactive with NGAL to detect an MMP-9/NGAL complex in the urine sample;
  - wherein the presence of the MMP-9/NGAL complex indicates the presence of a tissue remodeling-associated condition, thereby facilitating the diagnosis of the subject for a tissue remodeling-associated condition.
2. **(PREVIOUSLY PRESENTED)** The method of claim 1, wherein the tissue remodeling-associated condition is cancer.
3. - 5. **(CANCELED)**
6. **(PREVIOUSLY PRESENTED)** The method of claim 2, wherein the cancer is in cells of epithelial origin.
7. **(PREVIOUSLY PRESENTED)** The method of claim 6, wherein the cancer is selected from the group consisting of cancers of the nervous system, breast, prostate, retina, lung, skin, kidney, liver, pancreas, genito-urinary tract, and gastrointestinal tract.
8. **(CANCELED)**

Page 3 of 5

9. **(PREVIOUSLY PRESENTED)** The method of claim 2, wherein the cancer appears in cells of endodermal origin.
10. **(PREVIOUSLY PRESENTED)** The method of claim 2, wherein the cancer affects cells of bone or of hematopoietic origin.
11. – 40. **(CANCELED)**
41. **(PREVIOUSLY PRESENTED)** The method of claim 1, further comprising removal of contaminants from the urine prior to the detection step.
42. **(PREVIOUSLY PRESENTED)** The method of claim 41, wherein the urine is dialyzed.
43. **(CANCEL)** The method of claim 1, wherein the enzyme is detected by an electrophoretic pattern.
44. **(CANCEL)** The method of claim 43, wherein the electrophoretic pattern is a zymogram comprising a substrate.
45. **(CANCEL)** The method of claim 44, wherein the zymogram substrate is selected from the group consisting of gelatin, casein, fibronectin, vitronectin, plasmin, plasminogen, type IV collagen, and a derivative of type IV collagen.
46. **(CANCEL)** The method of claim 1, wherein the enzyme is detected immunochemically.
47. **(PREVIOUSLY PRESENTED)** The method of claim 1, wherein the MMP-9/NGAL complex is detected by a radio-immunoassay.
48. **(PREVIOUSLY PRESENTED)** The method of claim 1, wherein the MMP-9/NGAL complex is detected by an enzyme-linked immunoabsorbant assay.
49. – 81. **(CANCELED)**